Fosun Pharma vs Jiangsu Hengrui Pharmaceuticals
Fosun Pharma holds the steadier position overall because its spread across drug manufacturing, devices, hospitals, and distribution gives it more ways to absorb a bad quarter than Hengrui's narrower, oncology-heavy pipeline.
Fosun Pharma
Chinese drugmaker making generics, biosimilars, and licensed-out innovative drugs like GLP-1s
Jiangsu Hengrui Pharmaceuticals
China's largest listed drugmaker, oncology-heavy, licensing pipeline drugs to Western pharma majors
Dimension by dimension
| Dimension | Fosun Pharma | Jiangsu Hengrui Pharmaceuticals |
|---|---|---|
| Staying power of the core business | Rated hard to displace, with revenue spread across manufacturing, devices, hospitals, and distribution so no single product line carries the company. | Rated defensible for now, more concentrated in oncology drugs and pipeline licensing, so its fortunes lean harder on a smaller set of products. |
| Exposure to AI | AI is unlikely to absorb its business since drug manufacturing, hospitals, and distribution are physical and regulatory operations. | Same low exposure, since drug discovery and manufacturing still require physical trials, plants, and regulatory approval that AI does not replace. |
| How easily a giant copies them | Blocked, protected by manufacturing scale, hospital networks, and distribution relationships built over years. | Blocked, protected by its drug pipeline, patents, and licensing deals with Western pharma partners. |
| Pressure from rivals | Faces hard competition from Hengrui, Innovent, and Akeso for NRDL reimbursement slots, plus margin pressure from generics price cuts. | Faces the same set of domestic rivals, Innovent, Junshi, Akeso, and BeiGene, all fighting for the same oncology and PD-1 market share. |
| Profitability | FY2025 net profit of RMB 3.371 billion on RMB 41.662 billion revenue, a profit margin near 8 percent. | FY2025 net profit of RMB 7.72 billion on RMB 31.63 billion revenue, a profit margin near 24 percent despite lower total revenue. |
| R&D investment intensity | R&D spend of RMB 5.913 billion, about 14 percent of revenue. | R&D spend of RMB 8.72 billion, about 28 percent of revenue, nearly double the share Fosun commits. |
Questions people ask
- Fosun Pharma vs Hengrui Pharmaceuticals, which is in a stronger position long term?
- Fosun Pharma is rated hard to displace thanks to its spread across manufacturing, devices, hospitals, and distribution, while Hengrui is rated defensible for now because it leans more on its oncology pipeline. Both share the same low AI exposure and both are protected from being copied by a giant.
- Which has better profit margins, Fosun Pharma or Hengrui?
- Hengrui has the stronger margins, posting RMB 7.72 billion in net profit on RMB 31.63 billion revenue, near 24 percent. Fosun Pharma's net profit of RMB 3.371 billion on RMB 41.662 billion revenue works out to roughly 8 percent, well below Hengrui's rate despite Fosun's larger top line.
- Is Fosun Pharma or Hengrui more exposed to AI disruption?
- Neither company is considered likely to be absorbed by AI. Both Fosun and Hengrui run on physical drug manufacturing, clinical trials, and regulatory processes that AI does not replace, so their AI exposure ratings are identical.
- Who faces more competitive pressure, Fosun Pharma or Hengrui?
- Both face comparable pressure from the same cluster of Chinese biotech rivals, including Innovent, Akeso, and either Hengrui or Fosun competing against each other for NRDL reimbursement slots. Fosun additionally deals with generics pricing squeezes, while Hengrui's pressure concentrates more on oncology and PD-1 market share.
- Which company spends more on R&D, Fosun Pharma or Hengrui?
- Hengrui spends more relative to its size, putting RMB 8.72 billion into R&D, about 28 percent of revenue. Fosun spent RMB 5.913 billion, roughly 14 percent of revenue, a smaller share even though its total revenue is larger.